Gilead's HIV preventing med is not only groundbreaking, it could be the cure to what ails this stock.
These great stocks offer excellent yields, exceptional growth, and are terrific bargains.
Kite Pharma, bluebird bio, and ACADIA Pharmaceuticals all have price-shaking catalysts approaching that could bring big profits to investors.
With the Affordable Care Act's future in jeopardy, the insurance stock you want to own is the only one with zero exposure to the ACA: UnitedHealth.
Johnson & Johnson's new cancer treatment isn't just a drug; it's a $5 billion breakthrough.
A $14 billion spin-off of its over-the-counter drug unit would be great news for investors -- but will it happen?
Worried about the election's impact on pharma? Protect yourself with three great stocks relying on innovation, not price increases, for growth
With Amgen facing declining demand for its blockbusters, as well as a key failure with its $10 billion pipeline molecule, is this biotech worth buying?
Look past the scary headlines, and you may see a comeback in store for Gilead's investors.
Here’s how an exciting wave of recent discoveries is moving us closer to a cure.
Here’s how Celgene plans to rack up double-digit growth for decades to come.
Investors hit the jackpot with cardiac-care stocks last year. Here are three stocks primed to continue the heart-stopping gains.
Here's why cancer biotech Tesaro could be in the midst of a new lift-off.
This stock is back in the game with a pipeline full of near-term catalysts, superstar oncology drugs, and a 3.5% dividend yield.
Celgene’s deal-making genius tilts the odds in favor of its investors.
Johnson & Johnson has some oncology drug surprises up its sleeves that could drive further upside for this great stock.
Johnson & Johnson is launching a wearable that boldly embraces the huge diabetes market -- and could reignite its lagging medical-devices division.
These three high-risk/high-reward biotechs have drugs in late-stage trials and key catalysts just around the corner.
Apple is moving deeper into healthcare -- and big pharma is answering the call.
The two biotechs are closing in on explosive potential catalysts, including FDA filings and hoped-for approvals, but thin data could bring nasty surprises for investors.